[go: up one dir, main page]

SI1228039T1 - N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them - Google Patents

N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them

Info

Publication number
SI1228039T1
SI1228039T1 SI200030422T SI200030422T SI1228039T1 SI 1228039 T1 SI1228039 T1 SI 1228039T1 SI 200030422 T SI200030422 T SI 200030422T SI 200030422 T SI200030422 T SI 200030422T SI 1228039 T1 SI1228039 T1 SI 1228039T1
Authority
SI
Slovenia
Prior art keywords
guanidinoalkylamides
preparation
pharmaceutical preparations
preparations
pharmaceutical
Prior art date
Application number
SI200030422T
Other languages
English (en)
Slovenian (sl)
Inventor
Otmar Klingler
Gerhard Zoller
Elisabeth Defossa
Fahad Al-Obeidi
Armin Walser
James Ostrem
Original Assignee
Aventis Pharma Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland Gmbh filed Critical Aventis Pharma Deutschland Gmbh
Publication of SI1228039T1 publication Critical patent/SI1228039T1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40Acylated substituent nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/233Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SI200030422T 1999-10-30 2000-10-21 N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them SI1228039T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99121623A EP1095933A1 (en) 1999-10-30 1999-10-30 Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
PCT/EP2000/010395 WO2001032611A1 (en) 1999-10-30 2000-10-21 N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
EP00971396A EP1228039B1 (en) 1999-10-30 2000-10-21 N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them

Publications (1)

Publication Number Publication Date
SI1228039T1 true SI1228039T1 (en) 2004-10-31

Family

ID=8239305

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200030422T SI1228039T1 (en) 1999-10-30 2000-10-21 N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them

Country Status (31)

Country Link
US (2) US6472562B1 (xx)
EP (2) EP1095933A1 (xx)
JP (1) JP4658430B2 (xx)
KR (1) KR100981593B1 (xx)
CN (1) CN1249026C (xx)
AR (1) AR026257A1 (xx)
AT (1) ATE264837T1 (xx)
AU (1) AU776797B2 (xx)
BR (1) BR0015186A (xx)
CA (1) CA2389412C (xx)
CZ (1) CZ301855B6 (xx)
DE (1) DE60010113T2 (xx)
DK (1) DK1228039T3 (xx)
EE (1) EE05168B1 (xx)
ES (1) ES2220553T3 (xx)
HR (1) HRP20020372B1 (xx)
HU (1) HUP0203627A3 (xx)
IL (2) IL149209A0 (xx)
ME (1) MEP54708A (xx)
MX (1) MXPA02003805A (xx)
NO (1) NO328016B1 (xx)
NZ (1) NZ518607A (xx)
PL (1) PL203859B1 (xx)
PT (1) PT1228039E (xx)
RS (1) RS50471B (xx)
RU (1) RU2253651C2 (xx)
SI (1) SI1228039T1 (xx)
SK (1) SK286856B6 (xx)
TR (1) TR200201181T2 (xx)
WO (1) WO2001032611A1 (xx)
ZA (1) ZA200203294B (xx)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1644401E (pt) * 2003-07-04 2011-06-06 Lonza Ag Acesso melhorado para síntese em fase suportada
JP5637561B2 (ja) 2007-09-28 2014-12-10 ポートラ ファーマシューティカルズ, インコーポレイテッド 第Xa因子阻害剤に対する解毒剤およびその使用の方法
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
ES2647163T3 (es) 2008-01-04 2017-12-19 Intellikine, Inc. Derivados de isoquinolinona sustituidos con una purina útiles como inhibidores de la PI3K
RU2377990C1 (ru) * 2008-07-23 2010-01-10 Федеральное Государственное Образовательное Учреждение Высшего Профессионального Образования "Южный Федеральный Университет" Антитромботическое средство, влияющее на регуляцию функциональной активности тромбоцитов
US8455439B2 (en) 2008-11-14 2013-06-04 Portola Pharmaceuticals, Inc. Antidotes for factor Xa inhibitors and methods of using the same in combination with blood coagulating agents
PT2414517T (pt) 2009-03-30 2016-12-27 Portola Pharm Inc Antídotos para inibidores do fator xa e métodos de utilização dos mesmos
JP6163304B2 (ja) 2009-07-15 2017-07-12 ポートラ ファーマシューティカルズ, インコーポレイテッド 第Xa因子インヒビターの解毒剤の単位用量処方物およびその使用方法
KR20180080358A (ko) 2011-01-10 2018-07-11 인피니티 파마슈티칼스, 인코포레이티드 이소퀴놀린온 및 이의 고체 형태의 제조 방법
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
DK2914296T4 (da) 2012-11-01 2022-01-03 Infinity Pharmaceuticals Inc Behandling af cancere under anvendelse af PI3-kinase-isoform-modulatorer
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
CA3028718A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
CN110357800B (zh) * 2018-04-09 2022-07-26 青岛海生洋润生物科技有限公司 脯氨酸衍生物及其在制备治疗心脑血管疾病药物中的应用
CN115317474A (zh) * 2021-05-10 2022-11-11 中国海洋大学 一种苯酰胍衍生物在用于制备预防和治疗神经系统疾病或心血管系统疾病的药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU206372B (en) * 1990-09-03 1992-10-28 Richter Gedeon Vegyeszet Process for producing new oligopeptides which selectively inhibit proliferation of haemopoietic cells and pharmaceutical compositions comprising same
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5371072A (en) * 1992-10-16 1994-12-06 Corvas International, Inc. Asp-Pro-Arg α-keto-amide enzyme inhibitors
EP0680682A1 (en) 1993-01-20 1995-11-08 ALEXANDROVICS, Peter, John A line monitoring system
DE4326465A1 (de) 1993-01-20 1995-02-09 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5525623A (en) * 1993-03-12 1996-06-11 Arris Pharmaceutical Corporation Compositions and methods for the treatment of immunomediated inflammatory disorders
DE69532754T2 (de) 1994-04-26 2005-03-10 Aventis Pharmaceuticals, Inc. Faktor xa inhibitoren
HUT77313A (hu) * 1994-12-02 1998-03-30 Yamanouchi Pharmaceutical Co., Ltd. Amidino-naftil-származékok és sóik, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk
US6342504B1 (en) * 1994-12-13 2002-01-29 Corvas International, Inc. Aromatic heterocyclic derivatives as enzyme inhibitors
CA2301559A1 (en) * 1997-08-27 1999-03-04 Norihiko Kikuchi 3-amidinoaniline derivatives, activated blood coagulation factor x inhibitors, and intermediates for producing both
SE9703414D0 (sv) * 1997-09-23 1997-09-23 Astra Ab New compounds
ID27044A (id) 1997-12-24 2001-02-22 Aventis Pharma Gmbh Derivatif indole sebagai penghambat pada faktor xa
AU2074699A (en) * 1998-01-26 1999-08-09 Yamanouchi Pharmaceutical Co., Ltd. Novel benzene-fused heterocyclic derivatives or salts thereof
EP0987274A1 (en) 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
CA2372079A1 (en) * 1999-05-05 2000-11-09 Aaron H. Leeman Novel catechols as antimicrobial agents

Also Published As

Publication number Publication date
CA2389412A1 (en) 2001-05-10
AR026257A1 (es) 2003-02-05
NO20022022L (no) 2002-04-29
NZ518607A (en) 2003-10-31
RU2002114041A (ru) 2004-01-20
DE60010113D1 (de) 2004-05-27
PL354808A1 (en) 2004-02-23
JP4658430B2 (ja) 2011-03-23
DK1228039T3 (da) 2004-08-16
AU776797B2 (en) 2004-09-23
CN1249026C (zh) 2006-04-05
TR200201181T2 (tr) 2002-09-23
EP1228039B1 (en) 2004-04-21
CN1387508A (zh) 2002-12-25
WO2001032611A1 (en) 2001-05-10
MXPA02003805A (es) 2004-10-15
HUP0203627A3 (en) 2004-12-28
CA2389412C (en) 2009-12-01
US6472562B1 (en) 2002-10-29
CZ301855B6 (cs) 2010-07-14
YU29702A (sh) 2005-06-10
HUP0203627A2 (hu) 2003-03-28
PL203859B1 (pl) 2009-11-30
SK5782002A3 (en) 2002-10-08
ZA200203294B (en) 2003-01-29
RS50471B (sr) 2010-03-02
SK286856B6 (sk) 2009-06-05
ATE264837T1 (de) 2004-05-15
EP1228039A1 (en) 2002-08-07
RU2253651C2 (ru) 2005-06-10
DE60010113T2 (de) 2005-05-04
IL149209A (en) 2007-06-03
HRP20020372B1 (hr) 2011-01-31
HK1050673A1 (en) 2003-07-04
CZ20021489A3 (cs) 2002-07-17
US6664393B2 (en) 2003-12-16
IL149209A0 (en) 2002-11-10
AU1026501A (en) 2001-05-14
US20030162967A1 (en) 2003-08-28
KR20020047310A (ko) 2002-06-21
KR100981593B1 (ko) 2010-09-13
HRP20020372A2 (en) 2004-08-31
EE05168B1 (et) 2009-06-15
JP2003513066A (ja) 2003-04-08
EE200200199A (et) 2003-06-16
PT1228039E (pt) 2004-09-30
ES2220553T3 (es) 2004-12-16
MEP54708A (en) 2011-05-10
NO328016B1 (no) 2009-11-09
BR0015186A (pt) 2002-07-23
EP1095933A1 (en) 2001-05-02
NO20022022D0 (no) 2002-04-29

Similar Documents

Publication Publication Date Title
HUP0105414A3 (en) Pyrrolo-isoquinoline, azepino- and diazepino-indole derivatives, their use and pharmaceutical compisitions containing them
HUP0104905A3 (en) Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them
HUP0103793A3 (en) N-(2-aryl-propionyl)-sulfonamids, their use and pharmaceutical preparations containing them
IL127132A (en) Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them
AU3957600A (en) Piperidyl-imidazole derivatives, their preparations and therapeutic uses
AU5440901A (en) Cosmetic and/or pharmaceutical preparations
HUP0204081A3 (en) 4-pyrimidinyl-n-acyl-l-phenylalanines, pharmaceutical compositions containing them and their use
IL145150A0 (en) Pyridopyranoazepine derivatives, preparation and therapeutic use
EE05000B1 (et) 2'-asendatud 1,1'-bifenüül-2-karboksamiidid, nende kasutamine ja farmatseutilised preparaadid
HUP0202781A3 (en) Betha-carboline particulate form, pharmaceutical compositions containing it, their preparations and their use
HUP0203194A3 (en) Phenylpiperazines, pharmaceutical compositions containing them and their use
ZA200201057B (en) Radiopharmaceutical products and their preparation procedure.
HUP0203735A3 (en) 4-pyridinyl-n-acyl-l-phenylalanines, pharmaceutical compositions containing them and their use
IL149209A0 (en) N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
SI1043307T1 (en) 3-amino-3-arylpropan-1-ol-derivates, their preparation and their use
HUP0300334A3 (en) Pharmaceutical preparations and their manufacture
AU2438400A (en) Cosmetic and/or pharmaceutical preparations
AU4293800A (en) Cosmetic and/or pharmaceutical preparations
HUP0201810A3 (en) Sootepenseone and its derivatives, their preparation and use as medicament
IL146276A0 (en) Spiroimidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them
SI1043306T1 (en) 3-amino-3-arylpropan-1-ol-derivates, their preparation and use
HUP0203678A3 (en) Nitro-sulfobenzamide-derivatives, preparation and use thereof
IL132666A0 (en) Phytoestrogenic pharmaceutical preparations
IL146372A0 (en) Cinnamoylaminoalkyl-substituted benzenesulfonamide derivatives, processes for their preparation, their use and pharmaceutical preparations comprising them
HUP0203557A3 (en) Novel amidine derivatives, preparation and use thereof as medicines